Zn2+ inhibition of recombinant GABAA receptors:: an allosteric, state-dependent mechanism determined by the γ-subunit

被引:48
|
作者
Gingrich, KJ
Burkat, PM
机构
[1] Univ Rochester, Sch Med, Dept Anesthesiol, Rochester, NY 14642 USA
[2] Univ Rochester, Sch Med, Dept Physiol & Pharmacol, Rochester, NY 14642 USA
来源
JOURNAL OF PHYSIOLOGY-LONDON | 1998年 / 506卷 / 03期
关键词
D O I
10.1111/j.1469-7793.1998.609bv.x
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
1. The gamma-subunit in recombinant gamma-aminobutyric acid (GABA(A)) receptors reduces the sensitivity of GABA-triggered Cl- currents to inhibition by Zn2+ and transforms the apparent mechanism of antagonism from non-competitive to competitive. To investigate underlying receptor function ave studied Zn2+ effects on macroscopic and single-channel currents of recombinant alpha 1 beta 2 and alpha 1 beta 2 gamma 2 receptors expressed heterologously in HEK-293 cells using the patch-clamp technique and rapid solution changes. 2. Zn2+ present for > 60 s (constant) inhibited peak, GABA (5 mu M)-triggered currents of alpha 1 beta 2 receptors in a concentration-dependent manner (inhibition equation parameters: concentration at half-amplitude (IC50) = 0.94 mu M; slope related to Hill coefficient, S = 0.7) that was unaffected by GABA concentration. The gamma 2 subunit (alpha 1 beta 2 gamma 2 receptor) reduced Zn2+ sensitivity more than fiftyfold (IC50 = 51 mu M, S = 0.86); increased GABA concentration (100 mu M) antagonized inhibition by reducing apparent affinity (IC50 = 322 mu M, S = 0.79). Zn2+ slowed macroscopic gating of alpha 1 beta 2 receptors by inducing a novel slow exponential component in the activation time course and suppressing a fast component of control desensitization. For alpha 1 beta 2 gamma 2 receptors, Zn2+ accelerated a fast component of apparent desensitization. 3. Zn2+ preincubations lasting up to 10 s markedly increased current depression and activation slowing of alpha 1 beta 2 receptors, but had little effect on currents from alpha 1 beta 2 gamma 2 receptors. 4. Steady-state fluctuation analysis of macroscopic alpha 1 beta 2 gamma 2 currents (n = 5) resulted in control (2 mu M GABA) power density spectra that were fitted by a sum of two Lorentzian functions (relaxation times: 37 +/- 5.6 and 1.41 +/- 0.15 ms, means +/- S.E.M.). Zn2+ (200 mu M) reduced the total power almost sixfold and accelerated the slow (23 +/- 2.8 ms, P < 0.05) without altering the fast (1.40 +/- 0.16 ms) relaxation time. The ratio (fast/slow) of Lorentzian areas was increased by Zn2+ (control, 3.39 +/- 0.55; Zn2+, 4.9 +/- 0.37, P < 0.05). 5. Zn2+ (500 mu M) depression of previously activated current amplitudes (% control) for alpha 1 beta 2 gamma 2 receptors was independent of GABA concentration (5 mu M, 13.2 +/- 0.72%; 100 mu M, 12.2 +/- 2.9%, P < 0.8, n = 5). Both onset and offset inhibition time courses were biexponential. Onset rates were enhanced by Zn2+ concentration. Inhibition onset was also biexponential for preactivated alpha 1 beta 2 receptors with current depression more than fourfold less sensitive (5 mu M GABA, IC50 = 3.8 mu M, S = 0.84) relative to that in constant Zn2+. 6. The results lead us to propose a general model of Zn2+ inhibition of GABA(A) receptors in which Zn2+ binds to a single extracellular site, induces allosteric receptor inhibition involving two non-conducting states, site affinity is state-dependent, and the features of state dependence are determined by the gamma-subunit.
引用
收藏
页码:609 / 625
页数:17
相关论文
共 50 条
  • [21] Capturing state-dependent dynamic events of GABAA-receptors: a microscopic look into the structural and functional insights
    Payghan, Pavan V.
    Bera, Indrani
    Bhattacharyya, Dhananjay
    Ghoshal, Nanda
    JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2016, 34 (08): : 1818 - 1837
  • [22] Inhibition of Recombinant L-Type Voltage-Gated Calcium Channels by Positive Allosteric Modulators of GABAA Receptors
    Earl, Damien E.
    Tietz, Elizabeth I.
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2011, 337 (01): : 301 - 311
  • [23] Time- and Behavioral State-Dependent Changes in Posterior Hypothalamic GABAA Receptors Contribute to the Regulation of Sleep
    Volgin, Denys V.
    Lu, Jackie W.
    Stettner, Georg M.
    Mann, Graziella L.
    Ross, Richard J.
    Morrison, Adrian R.
    Kubin, Leszek
    PLOS ONE, 2014, 9 (01):
  • [24] Cross state-dependent memory retrieval between tramadol and ethanol: involvement of dorsal hippocampal GABAA receptors
    Jafari-Sabet, Majid
    Amiri, Shiva
    Sheibani, Mohammad
    Fatahi, Navid
    Aghamiri, Helia
    PSYCHOPHARMACOLOGY, 2024, 241 (01) : 139 - 152
  • [25] GABAA Receptors Containing the α2 Subunit Are Critical for Direction-Selective Inhibition in the Retina
    Auferkorte, Olivia Nicola
    Baden, Tom
    Kaushalya, Sanjeev Kumar
    Zabouri, Nawal
    Rudolph, Uwe
    Haverkamp, Silke
    Euler, Thomas
    PLOS ONE, 2012, 7 (04):
  • [26] Pregnenolone sulphate and Zn2+ inhibit recombinant rat GABAA receptor through different channel property
    Wang, M-D.
    Rahman, M.
    Zhu, D.
    Backstrom, T.
    ACTA PHYSIOLOGICA, 2006, 188 (3-4) : 153 - 162
  • [27] The unusual state-dependent affinity of P2X3 receptors can be explained by an allosteric two-open-state model
    Karoly, R.
    Mike, A.
    Illes, P.
    Gerevich, Z.
    MOLECULAR PHARMACOLOGY, 2008, 73 (01) : 224 - 234
  • [28] SB-205384 Is a Positive Allosteric Modulator of Recombinant GABAA Receptors Containing Rat α3, α5, or α6 Subunit Subtypes Coexpressed with β3 and γ2 Subunits
    Heidelberg, Laura S.
    Warren, James W.
    Fisher, Janet L.
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2013, 347 (01): : 235 - 241
  • [29] Zn2+ differentially modulates kinetics of GABAC vs GABAA receptors in carp retinal bipolar cells
    Han, MH
    Yang, XL
    NEUROREPORT, 1999, 10 (12) : 2593 - 2597
  • [30] Pentylenetetrazole-induced inhibition of recombinant γ-aminobutyric acid type A (GABAA) receptors:: Mechanism and site of action
    Huang, RQ
    Bell-Horner, CL
    Dibas, MI
    Covey, DF
    Drewe, JA
    Dillon, GH
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2001, 298 (03): : 986 - 995